American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR). ASCO plans should increase patient access to off-label drugs and match patients with [...]
At the recent American Society of American Oncology Meeting (ASCO), Dr. George Demetri, Director of the Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, presented results from a collaborative trial that indicates in [...]
Immunotherapy treatments garnered a great deal of attention at the Annual Meeting of the American Society of Clinical Oncology (ASCO). This article from the New York Times discusses this form of treatment and its [...]
ASCO was held again this year in Chicago. Over 32,000 medical professionals and exhibitors participated in what has become an international event. 53% of attendees now come from outside the US. It helps to know [...]
ASCO features many updates on GIST trials. Promising results for the immunotherapy approach to treating cancer dominated the annual conference of the ASCO and represent one of the biggest developments in cancer research since the advent [...]
Here is an overview of what Jim Hughes, Pete Knox and Jerry Call learned at ASCO. There will be a more in depth article to come.
This is a brief summary of abstracts presented at the 2013 GI ASCO meeting. Please note that abstracts have not been through a complete peer review process and are considered to be preliminary.
Two posters were presented by principal investigators in the Phase 2 and 3 trials of masitinib for the treatment of newly diagnosed GIST patients.
By Jim Hughes Here are updates from the American Society of Clinical Oncology conference on three GIST clinical trials. Panobinostat (HDAC) Phase 1 in 3rd Line GIST: LRG research Team member Sebastian Bauer, MD of Essen University [...]
Trial investigators for the Global Phase 3 GRID trial reported that the Bayer Pharmaceuticals’ drug regorafenib (BAY 73-4506) has the potential to fill the unmet need for advanced GIST patients progressing after imatinib and sunitinib. [...]
